Skip to main content
OpenTrials
Completed

NCT Number: NCT05995522

Effect of Vitamin K2 Over Osteocalcin, Leptin, Cytokines, and Cardiovascular Risk in Young Adults With Overweight and Obesity

The goal of this clinical trial is to compare de effect of vitamin K2 in young adults with overweight or obesity. The main questions to answer are:

What is the effect of Vitamin K2 supplementation on methylation, serum concentration of ucOC, cOC, Gas6, leptin, inflammatory markers, cardiometabolic risk factors, and cardiovascular risk in overweight or obese young adults? Participants will be assigned to one of two intervention groups where they will consume Vitamin K2 100 µg per day or cornstarch 500 mg per day for 90 days.

If there is a comparison group: Investigators will compare the supplementation group (Vitamin K2) with the placebo group (cornstarch) to see if vitamin K2 supplementation modifies methylation, increases serum vitamin K, osteocalcin, growth arrest-specific 6 protein serum concentration, decreases serum leptin concentration, inflammatory markers and reduces cardiometabolic risk factors and cardiovascular risk.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Guadalajara

Guadalajara, Jalisco, 44340, Mexico

About this study

Study Overview To meet the objectives of the project, two groups will be compared, one that will be supplemented with vitamin K and another of patients who will receive corn starch as a placebo. Patients are going to have a follow up during 3 months with periodic evaluations every 30 days.

This is a double-blind study, it is achieved by maintaining similarities in appearance, taste and smell between the treatments that will be delivered in the same vials, with same number of pills and identical in shape, color and consistency for each study group.

Patient recruitment will take place by disseminating information through physical and social media, once potential participants have been identified, they will be contacted and informed about the project, and if they decide to participate in the study, they will be asked to sign the informed consent.

Simple randomization will be performed using R software to assign participants to one of the study groups. A clinical history, anthropometric measurements and blood sampling shall be applied.

Nutritional recommendations based on the position of the Academy of Nutrition and Dietetics for the treatment of overweight and obesity and the healthy eating plate of Harvard University will be given. An appointment is to be scheduled every 30 days in order to provide the supplementation and follow-up. At the end, the pertinent statistical analyzes will be carried out.

Notification of adverse effects will be made in each of the sessions, in addition to this the participants will have the contact of the researchers to notify any anomaly.

Sample's size calculation

The sample size was calculated using the statistical formula for the comparison of two means. This estimate was made using the following formula:

n=2(Zα+Z[1-β]2xSD2/d2

Where:

n= sample size required in each group SD= standard deviation of the effect Zα: to the value of Z for a confidence level of 95% Z[1-β}: to the value of Z for a statistical power of 80% D= effect size A total of 19.72 patients per group were obtained. Considering a 20% loss, 24 patients are needed per study group.

Ethical considerations The study was approved by the Biosafety committee, research ethics committee and research committee of the University Center for Health Sciences, University of Guadalajara: CI-00421. The committees of the University have the authority to monitor and audit the study at any of its stages once it has been approved.

Objetives General objective Evaluate the effect of vitamin K2 supplementation on methylation, the serum concentration of total vitamin K, osteocalcin, growth arrest-specific 6 protein, leptin, inflammatory markers, cardiometabolic risk factors and cardiovascular risk in young Mexican adults with overweight or obesity.

Specific objectives

  • Compare the baseline variables between groups.
  • Compare the variable changes across the time within groups
  • Compare the variable changes across the time between groups

Statistical analysis The Shapiro-Wilk normality test is performed to determine whether the analysis will require parametric or non-parametric tests. Qualitative variables will be expressed as frequencies and percentages, while quantitative variables will be expressed as mean and standard deviation in parametric data or medians and ranges in non-parametric data.

Specific objective 1 Statistical technique T-student for independent samples if it has a normal distribution or by U-Mann Whitney for independent samples if it does not have a normal distribution

Specific objective 2 Variables with two measures Statistical technique T-student for paired samples if it has a normal distribution or the Wilcoxon signed-rank test if it does not have a normal distribution

Variables with more than two measures Statistical technique Repeated measures ANOVA if it has a normal distribution or the Friedman Test if it does not have a normal distribution

Specific objective 3 Statistical technique The effect size of the groups is compared with T-student for independent samples if it has a normal distribution or by U-Mann Whitney for independent samples if it does not have a normal distribution

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body Mass Index greater than 25 kg/m2 and less than 40 kg/m2
  • That they agree to participate in the study voluntarily and informed and sign the informed consent

Exclusion criteria

  • People with self-reported diagnosis of chronic kidney, gastrointestinal or systemic disease
  • Use of bile acid sequestrants drugs, insulin, glucocorticoids, contraceptives, bisphosphonates, thiazides, levetiracetam, thiazolidinediones, anticoagulants or estrogenic drugs and vitamin D, vitamin K, vitamin A, vitamin E, omegas or calcium supplements
  • Patients who are on a hypocaloric or low-fat diet
  • Self-reported pregnancy

Treatment and study plan

vitamin K2

Dietary Supplement

100 µg per day for 90 days

Other names: Nutricost Menaquinone-4 100 µg

Cornstarch

Other

500 mg per day for 90 days

Primary outcomes

  1. Osteocalcin serum concentration

    Time frame: Baseline and after 90 days of intervention

    ng/dL

  2. Vitamin K serum concentration

    Time frame: Baseline and after 90 days of intervention

    ng/dL

  3. Leptin serum concentration

    Time frame: Baseline and after 90 days of intervention

    ng/dL

  4. Tumour Necrosis Factor alpha serum concentration

    Time frame: Baseline and after 90 days of intervention

    pg/mL

  5. Interleukin-1 Beta serum concentration

    Time frame: Baseline and after 90 days of intervention

    pg/mL

  6. Interleukin-6 serum concentration

    Time frame: Baseline and after 90 days of intervention

    pg/mL

  7. Interleukin-4 serum concentration

    Time frame: Baseline and after 90 days of intervention

    pg/mL

  8. Interleukin-10 serum concentration

    Time frame: Baseline and after 90 days of intervention

    pg/mL

  9. Cardiovascular risk

    Time frame: Baseline, after 30, 60 and 90 days of intervention

    percentage

  10. LEP gene methylation

    Time frame: Baseline and after 90 days of intervention

    Methylated or unmethylated

Secondary outcomes

  1. Growth arrest-specific 6 protein serum concentration

    Time frame: Baseline and after 90 days of intervention

    ng/ml

  2. Global methylation

    Time frame: Baseline and after 90 days of intervention

    percentage

  3. Atherogenic indices

    Time frame: Baseline and after 90 days of intervention

    Value

  4. Triglycerides serum concentration

    Time frame: Baseline and after 90 days of intervention

    mg/dL

  5. Total cholesterol serum concentration

    Time frame: Baseline and after 90 days of intervention

    mg/dL

  6. HDL cholesterol serum concentration

    Time frame: Baseline and after 90 days of intervention

    mg/dL

  7. LDL cholesterol serum concentration

    Time frame: Baseline and after 90 days of intervention

    mg/dL

  8. VLDL cholesterol serum concentration

    Time frame: Baseline and after 90 days of intervention

    mg/dL

  9. Glucose serum concentration

    Time frame: Baseline and after 90 days of intervention

    mg/dL

  10. Blood pressure

    Time frame: Baseline, after 30, 60 and 90 days of intervention

    mmHg

  11. Insulin serum concentration

    Time frame: Baseline and after 90 days of intervention

    µIU/ml

  12. Weight

    Time frame: Baseline, after 30, 60 and 90 days of intervention

    kg

  13. Body mass index

    Time frame: Baseline, after 30, 60 and 90 days of intervention

    kg/m2

  14. Waist circumference

    Time frame: Baseline, after 30, 60 and 90 days of intervention

    cm

  15. Hip circumference

    Time frame: Baseline, after 30, 60 and 90 days of intervention

    cm

  16. Fat mass

    Time frame: Baseline, after 30, 60 and 90 days of intervention

    kg

  17. % fat

    Time frame: Baseline, after 30, 60 and 90 days of intervention

    percentage

  18. Lean mass

    Time frame: Baseline, after 30, 60 and 90 days of intervention

    kg

  19. Estimated energy consumption

    Time frame: Baseline, after 30, 60 and 90 days of intervention

    kcal/day

  20. Estimated protein consumption

    Time frame: Baseline, after 30, 60 and 90 days of intervention

    grams/day

  21. Estimated carbohydrates consumption

    Time frame: Baseline, after 30, 60 and 90 days of intervention

    grams/day

  22. Estimated fat consumption

    Time frame: Baseline, after 30, 60 and 90 days of intervention

    grams/day

  23. Estimated vitamin K consumption

    Time frame: Baseline, after 30, 60 and 90 days of intervention

    μg/day

Sponsors and collaborators

Lead sponsor

University of Guadalajara

Other

Registry information

Official study title

Effect of Vitamin K2 Supplementation and Its Association With Osteocalcin Serum Levels, Leptin, Th1/Th2 Cytokine Profile, and Cardiovascular Risk in Young Mexican Adults With Overweight and Obesity

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Aug 16, 2023
Registry last updated
May 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.